Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prospective Observational Study on Predictors of Early On-treatment Response and Sustained Virological Response in HCV-infected Patients Receiving Peginterferon Alfa-2a Plus Ribavirin

NCT01392742 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.

NCT NCT01392742
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01392742 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prospective Observational Study on Predictors of Early On-treatment Response and Sustained Virological Response in HCV-infected Patients Receiving Peginterferon Alfa-2a Plus Ribavirin
Lead sponsor
Hoffmann-La Roche
Phase
Observational
Overall status
Completed
Start date
May 31, 2011
Completion date
July 31, 2014
Enrollment
443 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

hepatitis c, chronic